{ "schemaVersion": 1, "organisationId": "O-2885d714a47748978bc29000dd4ada7d", "slug": "united-therapeutics-corp", "name": "UNITED THERAPEUTICS Corp", "updatedAt": "2026-10-02T11:40:25.509629Z", "sections": [ { "type": "OVERVIEW", "text": "United Therapeutics Corporation is a biotechnology and pharmaceutical company focused primarily on treatments for pulmonary hypertension and related lung diseases. Its marketed portfolio includes Tyvaso, Remodulin and Orenitram for pulmonary conditions, Unituxin for high-risk neuroblastoma, and Adcirca; the company also works on technologies intended to increase the availability of transplantable organs. [P55956413][P56584140][P68161096] Its stated public-benefit purpose is to advance therapies and technologies that address patients’ unmet medical needs and expand access to transplantable organs. [P68161096]\n\nFounded in 1996, the company reported 2025 revenue of approximately $3.18 billion. [P69652352][P10052865] At December 31, 2025, it had approximately 1,400 employees across 15 locations worldwide, with commercial activity extending beyond the United States through international distribution and sales. [P39279047][P23249511]\n[P55956413][P56584140][P68161096][P69652352][P10052865][P39279047][P23249511]", "updatedAt": "2026-10-02T11:40:25.509629Z" }, { "type": "PRODUCTS", "text": "United Therapeutics’ pulmonary hypertension products include TYVASO, an inhaled treprostinil solution delivered four times daily through an ultrasonic nebulizer, and TYVASO DPI, a dry-powder treprostinil formulation delivered four times daily using single-use cartridges and a portable inhaler. Both are used for pulmonary arterial hypertension (PAH); TYVASO is also indicated for pulmonary hypertension associated with interstitial lung disease. [P88456603][P68260303][P38526625][P25896333] REMODULIN is treprostinil injection for continuous subcutaneous or intravenous infusion to address PAH symptoms associated with exercise; its room-temperature stability, concentrated formulations and compatibility with company pump systems support ongoing infusion. ORENITRAM is an extended-release oral treprostinil tablet for PAH, indicated to delay disease progression and improve exercise capacity. [P86518041][P45043723][P53755652][P55326848][P70847371]\n\nOther marketed products include UNITUXIN (dinutuximab), a monoclonal antibody used with other medicines to treat high-risk pediatric neuroblastoma following response to first-line therapy, and ADCIRCA (tadalafil), a PDE-5 inhibitor for PAH that the company commercially distributes in the United States. [P56584140][P77116690][P57962465] The company also provides fee-for-service ex-vivo lung perfusion to transplant centers through Lung Bioengineering, using the XVIVO Perfusion System to assess donor-lung function; the service may help make lungs that might otherwise go unused available for transplant. [P10014555][P106699674]\n\nFor 2025, TYVASO products together accounted for 59% of total revenue, REMODULIN 17%, ORENITRAM 16% and ADCIRCA 1%. [P56185193][P86518041][P70847371][P77116690]\n[P88456603][P68260303][P38526625][P25896333][P86518041][P45043723][P53755652][P55326848][P70847371][P56584140][P77116690][P57962465][P10014555][P106699674][P56185193]", "updatedAt": "2026-10-02T11:40:25.509629Z" }, { "type": "GEOGRAPHY", "text": "United Therapeutics’ reported revenue is concentrated in the United States. In 2025, it recorded $3,037.0 million in U.S. revenue (95.4%) and $145.7 million in rest-of-world revenue (4.6%). For the first half of 2026, the corresponding figures were $1,477.8 million (94.4%) and $87.0 million (5.6%). The company reports foreign revenue as rest of world rather than breaking it down by country. [T13156057][T16734533]\n\nThe company identifies co-headquarters in Silver Spring, Maryland, and Research Triangle Park, North Carolina. Its Silver Spring campus includes laboratory and office space, product manufacturing and an ex-vivo lung perfusion center; its Research Triangle Park site includes research and development, manufacturing, warehousing and logistics operations. Other identified sites include an ex-vivo lung perfusion center in Jacksonville, Florida; a call-center facility in Melbourne, Florida; an aircraft-development facility in Bromont, Quebec; and the Organ Manufacturing Group in Manchester, New Hampshire. [P29836648][P3217437][P97361470][P120648799][P9231079][P105720567]\n\nThe company’s locations information lists a workforce presence across the United States, Canada and the United Kingdom, but does not give an employee breakdown by country. [https://www.unither.com/about-us/locations]\n[T13156057][T16734533][P29836648][P3217437][P97361470][P120648799][P9231079][P105720567][https://www.unither.com/about-us/locations][https://www.unither.com/about-us/locations]", "updatedAt": "2026-10-02T11:40:25.509629Z" }, { "type": "SEGMENTS", "text": "United Therapeutics reports one operating and reportable segment, managed on a consolidated basis. The segment focuses on developing and commercializing therapies for chronic and life-threatening conditions; the company does not report separate operating segments by product or therapeutic area. [P13748085]\n\nAs an analytical view—not a reported segment breakdown—FY2025 revenue was concentrated in pulmonary hypertension products: the Tyvaso franchise (Tyvaso DPI and nebulized Tyvaso) contributed about 59.0% of total revenue, Remodulin 16.6%, Orenitram 15.6%, Unituxin 7.1%, Adcirca 0.9%, and other products 0.8%. [T11490931] Tyvaso products treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease; Remodulin, Orenitram, and Adcirca are PAH therapies; Unituxin is used to treat neuroblastoma. [P88456603][P56185193][P86518041][P70847371][P62362945][P56584140]\n[P13748085][T11490931][T11490931][T11490931][T11490931][T11490931][T11490931][T11490931][T11490931][P88456603][P56185193][P86518041][P70847371][P62362945][P56584140]", "updatedAt": "2026-10-02T11:40:25.509629Z" }, { "type": "HISTORY", "text": "United Therapeutics was incorporated in Delaware as Lung Rx, Inc. on June 26, 1996, founded by Martine Rothblatt to develop a treatment for pulmonary arterial hypertension (PAH); it adopted the United Therapeutics name in December 1997 and held its initial public offering on June 17, 1999. [P69652352][https://ir.unither.com/faq] In 2002 and 2004, the FDA approved Remodulin for subcutaneous and intravenous infusion, respectively. [P86518041] The company added inhaled Tyvaso and Adcirca after FDA approvals in 2009. [https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/annual-reports/2009-Annual-Report.pdf]\n\nIn 2011, United Therapeutics acquired Revivicor, expanding its work into xenotransplantation and regenerative medicine. [https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/quarterly-reports/2011/4Q1110K.pdf] The FDA approved oral PAH treatment Orenitram in 2013, and in 2015 approved Unituxin for high-risk pediatric neuroblastoma; that year, founder Martine Rothblatt became co-CEO with Roger Jeffs. [https://ir.unither.com/press-releases/2013/12-20-2013-095453841][P56584140][P190496641] In 2021, the FDA expanded Tyvaso’s indication to pulmonary hypertension associated with interstitial lung disease, and the company converted to a public benefit corporation. [P88456603][P52976535] The FDA approved Tyvaso DPI in 2022, while in 2024 United Therapeutics reported a first human transplant of its investigational thymokidney under compassionate-use authorization. [https://ir.unither.com/press-releases/2022/05-24-2022][P10730759]\n[P69652352][P86518041][P56584140][P190496641][P88456603][P52976535][P10730759][https://ir.unither.com/faq][https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/annual-reports/2009-Annual-Report.pdf][https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/quarterly-reports/2011/4Q1110K.pdf][https://ir.unither.com/press-releases/2013/12-20-2013-095453841][https://ir.unither.com/press-releases/2022/05-24-2022]", "updatedAt": "2026-10-02T11:40:25.509629Z" } ], "sources": [ { "id": "P55956413", "href": "https://app.finbar.com/go?id=P55956413", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P56584140", "href": "https://app.finbar.com/go?id=P56584140", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P68161096", "href": "https://app.finbar.com/go?id=P68161096", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P69652352", "href": "https://app.finbar.com/go?id=P69652352", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P10052865", "href": "https://app.finbar.com/go?id=P10052865", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P39279047", "href": "https://app.finbar.com/go?id=P39279047", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P23249511", "href": "https://app.finbar.com/go?id=P23249511", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P88456603", "href": "https://app.finbar.com/go?id=P88456603", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P68260303", "href": "https://app.finbar.com/go?id=P68260303", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P38526625", "href": "https://app.finbar.com/go?id=P38526625", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P25896333", "href": "https://app.finbar.com/go?id=P25896333", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P86518041", "href": "https://app.finbar.com/go?id=P86518041", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P45043723", "href": "https://app.finbar.com/go?id=P45043723", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P53755652", "href": "https://app.finbar.com/go?id=P53755652", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P55326848", "href": "https://app.finbar.com/go?id=P55326848", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P70847371", "href": "https://app.finbar.com/go?id=P70847371", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P77116690", "href": "https://app.finbar.com/go?id=P77116690", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P57962465", "href": "https://app.finbar.com/go?id=P57962465", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P10014555", "href": "https://app.finbar.com/go?id=P10014555", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P106699674", "href": "https://app.finbar.com/go?id=P106699674", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P56185193", "href": "https://app.finbar.com/go?id=P56185193", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "T13156057", "href": "https://app.finbar.com/go?id=T13156057", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "T16734533", "href": "https://app.finbar.com/go?id=T16734533", "label": "UNITED THERAPEUTICS Corp — Full financial report (2026 Q 2)", "documentId": "D-fefe8d2056394bea9aaa1461ba92506f" }, { "id": "P29836648", "href": "https://app.finbar.com/go?id=P29836648", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P3217437", "href": "https://app.finbar.com/go?id=P3217437", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P97361470", "href": "https://app.finbar.com/go?id=P97361470", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P120648799", "href": "https://app.finbar.com/go?id=P120648799", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P9231079", "href": "https://app.finbar.com/go?id=P9231079", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P105720567", "href": "https://app.finbar.com/go?id=P105720567", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "https://www.unither.com/about-us/locations", "href": "https://www.unither.com/about-us/locations", "label": "www.unither.com" }, { "id": "P13748085", "href": "https://app.finbar.com/go?id=P13748085", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "T11490931", "href": "https://app.finbar.com/go?id=T11490931", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "P62362945", "href": "https://app.finbar.com/go?id=P62362945", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "https://ir.unither.com/faq", "href": "https://ir.unither.com/faq", "label": "ir.unither.com" }, { "id": "https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/annual-reports/2009-Annual-Report.pdf", "href": "https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/annual-reports/2009-Annual-Report.pdf", "label": "ir.unither.com" }, { "id": "https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/quarterly-reports/2011/4Q1110K.pdf", "href": "https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/quarterly-reports/2011/4Q1110K.pdf", "label": "ir.unither.com" }, { "id": "https://ir.unither.com/press-releases/2013/12-20-2013-095453841", "href": "https://ir.unither.com/press-releases/2013/12-20-2013-095453841", "label": "ir.unither.com" }, { "id": "P190496641", "href": "https://app.finbar.com/go?id=P190496641", "label": "UNITED THERAPEUTICS Corp — Full financial report (2015 Y)", "documentId": "D-7bbe3980f82845a0b0e77998fe84c760" }, { "id": "P52976535", "href": "https://app.finbar.com/go?id=P52976535", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" }, { "id": "https://ir.unither.com/press-releases/2022/05-24-2022", "href": "https://ir.unither.com/press-releases/2022/05-24-2022", "label": "ir.unither.com" }, { "id": "P10730759", "href": "https://app.finbar.com/go?id=P10730759", "label": "UNITED THERAPEUTICS Corp — Full financial report (2025 Y)", "documentId": "D-1bae5f3ec70f4a85bc5e9a8a9aaa6baa" } ] }